A multi-institutional study led by the Icahn School of Medicine at Mount Sinai reports one-third of patients with relapsed or ...

The dramatic bend in the curve of cancer deaths didn’t happen by accident — it’s the compound interest of three revolutions.

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

A long-term follow-up of early total therapy trials suggests that up to one-third of patients with newly diagnosed multiple ...

This will be Maharashtra’s first public hospital where not just cancer, but also inherited blood disorders in both children ...

During a live event, Taewoong Choi, MD, discussed the current state of therapy for transplant-ineligible newly diagnosed ...

New data from the IRAKLIA and IZALCO trials, presented at the 2025 ASCO Annual Meeting, demonstrate that subcutaneous ...

As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

At 38, author Jonathan Gluck was diagnosed with blood cancer and given less than three years to live. He's written a memoir ...

ASCO Data Shows New Therapy Keeps Myeloma Patients in Remission for 5+ Years. Here's what you need to know about the ...

Results from the Phase Ib/II CARTITUDE-1 trial demonstrated that a single infusion of Carvykti delivered durable, ...

The FDA is expected to decide on treatments for multiple myeloma, NSCLC, melanoma, phenylketonuria, and 2 rare kidney diseases.